StockData
BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

BioLineRx Ltd.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026
$1.98−0.03 (-1.49%)

Close on Oct 19, 2026

Market cap
$5.28B
P/E (TTM)
–
Dividend yield
–

BioLineRx Ltd. revenue by segment

No segment breakdown reported

BioLineRx does not break out revenue by segment, region or product in the tagged data of its filings for this period type.